8-K current report · filed Nov 16, 2026

Keros Therapeutics, Inc. (KROS) 8-K Current Report: November 16, 2026

Item 8.01Item EX-99.1KROS overview

Short answer

Keros Therapeutics, Inc. (KROS) filed an 8-K current report with the SEC on November 16, 2026 reporting Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). $5 million common-stock repurchase program approved after receiving a $20 million Takeda development milestone.

Keros Therapeutics, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 8.01 · Other Events

  • $5 million common-stock repurchase program approved after receiving a $20 million Takeda development milestone
  • Cash and equivalents totaled $259.5 million as of September 30, 2026
  • Post-milestone and repurchase cash expected to fund operations and capital expenditures into 2029
  • Buyback signals management confidence while returning a portion of milestone proceeds to shareholders

Item EX-99.1 · Exhibit EX-99.1

  • $5 million share repurchase authorization following $20 million elritercept development milestone payment from Takeda
  • Capital return signals management views repurchases as an attractive use of milestone proceeds
  • Repurchases may occur in open-market transactions, with timing and amounts dependent on market conditions
  • Program creates no purchase obligation and may be modified, suspended or discontinued at any time

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Keros Therapeutics, Inc. 8-K filings

Get the next KROS 8-K as it lands

Follow KROS for push alerts, or ask the research agent what this filing means.